CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Sanofi-Aventis U.S. LLC v. Amneal Pharmaceuticals LLC

1:17-cv-00039

Overview

Case Number 1:17-cv-00039
Filing Date 2017-01-12
Status Terminated
Termination Date 2017-10-11
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Amneal Pharmaceuticals Co. India Private Limited NPE (University / Research)

Represented By

1 Attorneys Listed

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Avenue, Suite 200, Wilmington, DE 19801

Amneal Pharmaceuticals LLC Operating Company

Represented By

3 Attorneys Listed

Samuel S. Park

UNDELIVERABLE EMAIL 10/31/2018

Jovial Wong

Email: jwong@winston.com

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Avenue, Suite 200, Wilmington, DE 19801

Plaintiff

Genzyme Corporation NPE (Individual / Inventor)

Represented By

6 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Brandon J. Kennedy

Email: kennedy@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Sanofi Operating Company

Represented By

6 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Brandon J. Kennedy

Email: kennedy@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Aventisub LLC Operating Company

Represented By

6 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Brandon J. Kennedy

Email: kennedy@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Sanofi-Aventis U.S. LLC Operating Company

Represented By

6 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Brandon J. Kennedy

Email: kennedy@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): GB 🇺🇸 US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6794410
Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Filed: 2002-04-01
Issued: 2004-09-21
Expired (Term Ended) +1639d PTA
Expires: 2026-09-26
US8802735
(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Filed: 2012-03-16
Issued: 2014-08-12
Active (5.3 yrs remaining)
Expires: 2032-03-16
US9186346
Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Filed: 2014-02-04
Issued: 2015-11-17
Active (7.2 yrs remaining)
Expires: 2034-02-04

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1639 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

5

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Procedural / Extension Motion 4 Claim Construction / Markman Filing 1

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending
ORAL ORDER re (21 in 1:16-cv-01298-GMS, 21 in 1:17-cv-00024-GMS, 19 in 1:17-cv-00027-GMS, 16 in 1:17-cv-00003-GMS, 21 in 1:17-cv-00018-GMS, 17 in 1:17-cv-00019-...
Entry #— • 2017-06-13
Procedural / Extension Motion Pending
SO ORDERED - re (16 in 1:17-cv-00039-GMS) STIPULATION TO EXTEND TIME to File Joint Status Report and Proposed Scheduling Order to May 11, 2017 filed by Aventisu...
Entry #— • 2017-03-24
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to File Joint Status Report and Proposed Scheduling Order to May 11, 2017 - filed by Aventisub LLC, Genzyme Corporation, Sanofi, Sano...
Entry #16 • 2017-03-23 Document →
Procedural / Extension Motion Pending
SO ORDERED - re 10 STIPULATION TO EXTEND TIME to Respond to Complaint to March 17, 2017 filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Co. India Pr...
Entry #— • 2017-01-30
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Respond to Complaint to March 17, 2017 - filed by Amneal Pharmaceuticals Co. India Private Limited, Amneal Pharmaceuticals LLC. (G...
Entry #10 • 2017-01-27 Document →

Docket Entries

(54 total)
Pleading / Complaint

COMPLAINT for PATENT INFRINGEMENT filed against Amneal Pharmaceuticals Co. India Private Limited, Amneal Pharmaceuticals LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2064142.) - filed by Sanofi-Aventis U.S. LLC, Aventisub LLC, Sanofi, Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(nmg) (Entered: 01/13/2017)

Entry #1 • 2017-01-12
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) (Entered: 01/13/2017)

Entry #2 • 2017-01-12
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/1/2016. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 3/12/2020. (nmg) (Entered: 01/13/2017)

Entry #3 • 2017-01-12
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1; US 8,802,735 B2; US 9,186,346 B2. (nmg) (Entered: 01/13/2017)

Entry #4 • 2017-01-12
1

No Summons Issued. (nmg)

Entry #5 • 2017-01-12
1
No Actions

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc